A Phase 3 interventional study of Experimental group: ticagrelor and Control group: placebo in Subarachnoid Hemorrhage, Aneurysmal, Brain Ischemia and Endovascular Procedure, sponsored by University Hospital, Toulouse. Not yet recruiting at 7 sites in France. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by University Hospital, Toulouse · Phase 3, Interventional, and Treatment
Among aneurysmal subarachnoid hemorrhage (aSAH) survivors, ischemic injuries such as peri procedural thromboembolic events (TEE) and delayed cerebral ischemia (DCI) represent the most important disabling complications. However, preventive strategies are limited. Platelet activation mechanisms play a critical role in the pathophysiology of TEE and DCI. The results of several meta analyses suggested that use of antiplatelet drugs (APD) could reduce the risk of TTE/DCI. We aim to evaluate in patients with a low grade aSAH (WFNS 1 to 3) that occurred for less than 72 hours ago, the effect of 14 days course of ticagrelor vs placebo, initiated at the beginning of the endovascular treatment of the aneurysm, on the ischemic complications (peri-procedural symptomatic and asymptomatic TEE and/or neurological worsening due to DCI) occurring within 14 days of the endovascular treatment of the aneurysm.
After aSAH, ischemic complications such as peri-procedural TEE and DCI prevalence are as high as 15 and 30% of the patients respectively. They are the main causes of disability in patients who survive the initial bleeding. The diagnoses of TEE and DCI may be difficult in patients experiencing high grade aSAH contrariwise to low grade where clinical exam and reliable imaging of brain ischemia could be performed. In addition, TEE/DCI dramatically impact the prognosis of these patients who had no/minor initial deficit. Platelet activation and thrombo-inflammatory mechanisms play a critical role in the pathophysiology of TEE and DCI through multiple pathways. Several APD have been evaluated to mitigate TEE/DCI risk with heterogeneous results. A recent metanalysis suggested that APD could reduce TEE incidence by 13 %. Interestingly patients receiving mono or dual APD just before aneurysmal repair did not experience an increased hemorrhagic risk. Regarding DCI, aspirin failed to demonstrate any benefit in an European randomized controlled trial while 3 recent meta-analyses suggested that APD use may be associated with a relative risk reduction of 40-50%. Hence, in the absence of positive trials no APD use is not recommended for the management of aSAH. Compared to previous APD used in aSAH, Ticagrelor, a reversible P2Y12 receptor inhibitor, has a promising profile to control TEE/ DCI: stronger and shorter antiplatelet action as well as vasodilatory and anti-inflammatory effects.
Two hundred and seventy-four patients will be randomized 1:1 in Ticagrelor or placebo group within 72hrs of aneurysm rupture in a multicentre prospective double-blind, parallel group study. Ticagrelor/placebo will be administered orally just before the endovascular treatment of the aneurysm with a loading dose of 180 mg, followed by 90 mg twice a day during 2 weeks. We will assess a composite primary end point based on the occurrence of ischemic complications: peri-procedural asymptomatic and symptomatic TEE and/or neurological deterioration due to DCI. During the first 24H, TEE is defined by clotting or arterial occlusion on angiography during endovascular procedure and/or 24hrs-MRI infarctions and/or neurological deterioration defined by the worsening ≥2pts from baseline on NIHSS performed immediately after the intervention, then every 6 hours. From day 2 to 15, multi daily clinical monitoring using NIHSS will be performed to assess the occurrence of neurological deterioration due to DCI, defined as worsening ≥2pts on NIHSS, lasting for at least 2hrs. A brain imaging- MRI recommended- is needed in the case of neurological deterioration to confirm its ischemic mechanism. Rescue therapies for DCI will be feasible according to a decisional algorithm. Systematic MRI will be performed within the 24hrs of the endovascular procedure and 15 days after randomization in order to detect, confirm and quantify cerebral infarcts. At 3 months, visit will include functional outcome with the mRS and the GOSE, cognitive functions with the Montreal Cognitive Assessment (MoCA) and quality of life using EQ-5D. Any hemorrhagic complication related to SAH (rebleeding during the procedure, hydrocephalus requiring ventricular drain, intracerebral hemorrhage) other major bleedings and side effects of the treatment such as dyspnea will be carefully monitored and reported.
510 studies on the registry are indexed under Subarachnoid Hemorrhage; 128 are open to participants now.
This study's planned enrollment of 274 is above the median of 57 across 264 interventional studies indexed under Subarachnoid Hemorrhage.
Browse Subarachnoid Hemorrhage studies →University Hospital, Toulouse is the lead sponsor of 807 studies on the registry; 209 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Experimental group: ticagrelor
Drug: Control group: placebo
Patients with a low grade aSAH receiving ticagrelor. Ticagrelor will be administered orally just before the endovascular treatment of the ruptured aneurysm with a loading dose of 180mg, followed by 90 mg twice a day during 2 weeks.
Patients with a low grade aSAH receiving placebo. Placebo will consist of tablets identical to ticagrelor ones, administered orally with a loading dose of 2 tablets, followed by 1 tablet twice a day during 2 weeks
Effect of tricagrelor on the ischemic complications: peri-procedural thromboembolic events
It will be assessed by the occurence of symptomatic and asymptomatic peri-procedural thromboembolic events within the first 24 hours after the procedure. These events can be : * angiographic : any event with clotting near the neck of the aneurysm or in distal branches and parent vessel occlusion in any vascular territory during procedure, and/or * Clinical: worsening neurological deficit ≥2 points on NHISS from baseline after the procedure not attribuable to other causes, and/or * Imaging: acute infarctus on 24h MRI The NIHSS (National Institutes of Health Stroke Scale) is a clinical scale used primarily to assess the severity of a stroke. It consists of 15 items which assigns a score ranging from 0 to 42 (0 corresponds to no measurable deficit and 42 to the maximum neurological deficit).
Time frame: 24 hours
Effect of tricagrelor on the ischemic complications: neurological deterioration
It will be assessed by the occurence of neurological deterioration due to delayed cerebral ischemia DCI within 14 days of the endovascular treatment. It will be caracterized by a worsening deficit (≥2 points on NIHSS scale from the previous evaluation), lasting at least 2 hours, not attributed to other causes.
Time frame: 14 days
Peri-procedural asymptomatic and symptomatic TEE: angiographic
It will be assessed by the occurence of one peri-procedural angiographic TEE that is, any event with clotting near the neck of the aneurysm or in distal branches and parent vessel occlusion in any vascular territory during procedure within 24 hours of aneurysmal treatment.
Time frame: 24 hours
Peri-procedural asymptomatic and symptomatic TEE: clinical
It will be assessed by the occurence of at least one peri-procedural clinical TEE that is, symptomatic ischemic lesions defined by a worsening ≥2pts on NIHSS from baseline, not attributable to other causes within 24 hours of aneurysmal treatment.
Time frame: 24 hours
Peri-procedural asymptomatic and symptomatic TEE: ischemic lesion
It will be assessed by the occurence of at least one severe symptomatic ischemic lesion defined by worsening \>4 points on NIHSS from baseline within 24 hours after the aneurysmal treatment.
Time frame: 24 hours
Peri-procedural asymptomatic and symptomatic TEE: imaging
It will be assessed by the occurence of at least one peri-procedural TEE that is, acute infarctus on MRI performed within 24 hours after endovascular treatment.
Time frame: 24 hours
Neurological deterioration and asymptomatic lesions on MRI due to DCI
It will be assessed by the occurence of at least one neurological deterioration due to DCI (worsening ≥2pts on NIHSS compared with previous evaluation), lasting at least 2 hrs, not attributed to other causes after a brain imaging at day 15.
Time frame: 15 days
Neurological deterioration and asymptomatic lesions on MRI due to DCI: severe neurological deterioration
It will be assessed by the occurence of at least one severe neurological deterioration due to DCI defined by worsening \>4 points on NIHSS compared to previous evaluation, at day 15.
Time frame: 15 days
Neurological deterioration and asymptomatic lesions on MRI due to DCI: asymptomatic MRI lesions
It will be assessed by the occurence of new infarctus on MRI at day 15.
Time frame: 15 days
Neurological deterioration and asymptomatic lesions on MRI due to DCI: ischemic event
It will be assessed by the occurence of at least one ischemic event (clinical/MRI) related to DCI, at day 15.
Time frame: 15 days
Total incidence of ischemic events per patient
It will be assessed by the combined incidence of all ischemic events: sum of both type of ischemic events (related to TEE and/or DCI) at day 15.
Time frame: 15 days
Need for rescue therapy during embolization and/or DCI
It will be assessed by the rate of rescue therapy for angiography defined by any mechanical maneuvers (catheter aspiration, stentrievers use or any pharmacological intra-arterial or intravenous therapies) within 14 days of treatment.
Time frame: 14 days
Aneurysm occlusion
It will be assessed by the quality of the aneurysm occlusion evaluated at procedure completion, 24 hours and 3 months MRI/MRA based on the Raymond-Roy classification. The Raymond-Roy classification is an angiographic classification used to describe the degree of aneurysm occlusion: * Class 1: complete occlusion * Class 2: residual neck * Class 3: residual aneurysm.
Time frame: 3 months
Clinical outcome at 3 months: good functionnal outcome (disability and functional dependence)
It will be assessed by the Modified Rankin Scale (mRS) with a score that must be below 3. It is a clinical scale that measures a patient's degree of disability and functional dependence on a scale from 0 to 6 (the higher the score, the greater the disability and dependence). It will be performed at visit 16 (3 months).
Time frame: 3 months
Clinical outcome at 3 months: good functional outcome (disability and recovery)
It will be assessed by the GOSE (Glasgow Outcome Scale-Extended) with a score that must be above 5. It is a scale used to assess the level of recovery and disability following a brain injury; it has 8 levels, ranging from 1 (death) to 8 (good recovery). It will be performed at visit 16 (3 months).
Time frame: 3 months
Clinical outcome at 3 months: quality of life
It will be assessed by the EQ-5D questionnaire at visit 16 (3 months). It is a health-related quality of life questionnaire that assesses five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each item is rated on a 5-point scale, resulting in a total score ranging from 1 to 100, where 0 represents the worst possible health status and 100 represents the best.
Time frame: 3 months
Clinical outcome at 3 months: cognitive deterioration
The rate of cognitive deterioration will be defined by a MoCA score below or equal to 25, performed at visit 16 (3 months). The MoCA (Montreal Cognitive Assessment) is a screening test for cognitive disorders that yields a score ranging from 0 to 30 (where 0 indicates severely impaired cognitive function and 30 indicates optimal performance).
Time frame: 3 months
Clinical outcome at 3 months: deaths
It will be assessed by the number of deaths occuring during the totality of the research (3 months).
Time frame: 3 months
Occurence of adverse events
All adverse events during the totality of the research (3 months) will be collected.
Time frame: 3 months
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Nov 2026; primary completion for Dec 2029, 36 months later.
Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Nov 6, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ticagrelor
University Hospital, Toulouse →